<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

We take lung
cancer personally

Early diagnosis and swift treatment are critical to changing the lung cancer landscape. Our focus on clinical needs across the lung cancer continuum of care helps patients and providers confidently navigate the diagnostic pathway and optimal treatment decisions.

young male doctor mosaic
Interested in COVID-19 Information?

Blood-based testing strategies to support clinical decision-making from diagnosis through monitoring

middle aged man in black polo shirt

nodify-lung

Nodify Lung® testing consists of two blood-based proteomic tests, the Nodify CDT® and Nodify XL2® tests, designed to help providers quickly and confidently decipher the risk of malignancy of a lung nodule.

Reclassifies 40% of patients with low to moderate risk lung nodules into the very low or the high-risk groups1
Helps physicians to identify lung cancer earlier and reduce unnecessary procedures on benign nodules
Supports shared decision-making with a personalized risk assessment
$0 out of pocket for Medicaid and covered Medicare beneficiaries
middle aged woman crossing her arms

IQ Lung logo

Biodesix IQLung™ Treatment Guidance testing consists of the GeneStrat® targeted test, the GeneStrat NGS™ genomic test and the VeriStrat® proteomic test for a broader view of each patient's disease state, with average results ready in 72 hours or less.* IQLung testing empowers care teams with a testing strategy for any stage of non-small cell lung cancer (NSCLC) and delivers timely biological insights to help expedite personalized treatment decisions.

Expedite time to personalized treatment for each patient
Drive optimal treatment decisions by giving physicians genomic and proteomic insights
Enhance existing workflows with a simple blood draw
Informs physicians with meaningful data to aid in treatment options at any stage of lung cancer
scientist removing test tube from rack

In Development

Learn more about our efforts to expand the clinical understanding of our current tests and clinical studies exploring new and ongoing diagnostic challenges.

Data-driven diagnostic solutions

We are here for you

Our in-house Customer Care experts are only a click away

Our data library

Explore our library of publications, abstracts, videos, and more

*72 Hours represents the average turnaround time for testing, individual test turnaround times may vary.
1 Springmeyer et al. ATS Annual Meeting, May 14-19, 2021; San Diego, CA